This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

First Double-Blind, Placebo-Controlled Published Study Of CYPLEXINOL® Finds Significant Improvement In Pain, Stiffness And Quality Of Life In Patients With Osteoarthritis

TOMS RIVER, N.J., April 10, 2013 /PRNewswire/ --  ZyCal Bioceuticals, Inc. today announced results of the first double-blind, placebo-controlled study evaluating the benefits of Cyplexinol ® in alleviating symptoms of osteoarthritis. The results were published in the April/ May 2013 issue of Integrative Medicine: A Clinician's Journal, ( a peer-reviewed publication providing practitioners with a practical and comprehensive approach to integrating alternative therapies with conventional medicine . According to the study, participants treated with Cyplexinol ® reported a significant decrease in pain and stiffness, and a significant increase in quality of life (QOL) as compared to those treated with placebo.

Cyplexinol ® is a naturally-derived, biologically active protein complex consisting of bone morphogenetic proteins (BMPs) which stimulate bone and cartilage growth and fight inflammation. Cyplexinol ® is the active ingredient in Ostinol™ which is now available directly to consumers as an oral supplement from ZyCal Bioceuticals as well as through Chiropractors and Naturopathic physicians without a prescription.

"Using BMPs to rebuild cartilage and down-regulate inflammatory pathways is a new and exciting approach to managing the debilitating symptoms of osteoarthritis," said Richard Garian, DC, CCSP, one of the study investigators who also co-authored the paper. "For the first time, using rigorous study methods, we were able to demonstrate significant and measurable improvements in pain relief, functionality and quality of life in patients treated with an oral BMP - complex, Cyplexinol ® in as little as one week."

In this randomized, double-blind, placebo-controlled clinical trial, 87 participants diagnosed with moderate-to-severe osteoarthritis joint pain in a weight-bearing joint (the hip or knee) were randomized to receive a daily dose of either 150 mg of Cyplexinol ® or placebo for 12 weeks. Investigators measured the three primary endpoints – pain, stiffness and QOL – using the Western Ontario and McMaster University (WOMAC) Osteoarthritis Index 3.1. Change in WOMAC scores from baseline to week 1, week 6 and week 12 were calculated.   

Key findings demonstrated that participants treated with Cyplexinol ® reported:

  • Significant improvement (decrease) in pain, stiffness, and QOL was observed on the WOMAC subscales for the treatment group. The change in the group's mean scores reached significance in as early as 1 week, with a decrease in pain of 1.57 points (95% CI, 0.74-2.39; P<.0001
  • Significant improvement (decrease) in pain by 3.35 points (p<0.0001) at week 12 versus those treated with placebo who reported an increase in pain by 0.35 points (p>0.05)
  • Significant improvement (decrease) in stiffness by 2.95 points (p<0.0001) at week 12 versus those treated with placebo who reported a slight decrease in stiffness by 0.18 points (p>0.05)
  • Significant improvement (increase) in QOL by 3.12 points (p<0.0001) at week 12 versus those treated with placebo who reported a decrease in QOL by 0.40 points (p>0.05)

"The ability of bone morphogenetic proteins (BMPs) to stimulate bone and cartilage growth is well-documented in peer-reviewed literature and for decades, orthopedic surgeons have used BMPs intra-operatively to treat patients with bone-healing difficulties," said James Scaffidi, President and CEO of ZyCal Bioceuticals, Inc. "In creating Cyplexinol ®, the first oral BMP - complex, we are able to bring the benefits of BMPs to the millions of people suffering from debilitating bone and joint conditions."

About ZyCal Bioceuticals, Inc.ZyCal Bioceuticals, Inc. is an innovative nutrigenomics company focused on developing novel biologically active ingredients and products to promote bone and joint health. The company's proprietary ingredient, Cyplexinol ® is the first oral, naturally - derived BMP - complex. Cyplexinol ® works by stimulating stem cells to grow bone and cartilage tissue as well as helps in the fight against inflammation. The BMPs found in Cyplexinol ® are supported by 40 years of scientific and medical research and have been used intra-operatively by surgeons for 25 years. Cyplexinol ® is manufactured in a cGMP certified facility, available for licensing and marketed directly to consumers as Ostinol™. For more information on licensing Cyplexinol ® or to order Ostinol™ call 1-888-779-9225 ext.104 or visit

Contacts:Company Contact:ZyCal Bioceuticals, Inc. Marc Gawrych, (888) 779-9225 Ext. 104

Media Contact: Jennifer Ferris-Azzariti, (888) 779-9225 Ext. 110

SOURCE ZyCal Bioceuticals, Inc.

Copyright 2011 PR Newswire. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

Select the service that is right for you!

Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!


DOW 18,053.71 +23.50 0.13%
S&P 500 2,088.77 +6.89 0.33%
NASDAQ 4,806.8590 +33.3870 0.70%

Brokerage Partners

Rates from

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs